• Home

  • Documents

  • Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP T... · ment occurred in all patients after...
6

Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP T... · ment occurred in all patients after 24, 31, and 26 days, seem to be especially susceptible to cardiac toxicity, the

  • Upload
    others

  • View
    1

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP T... · ment occurred in all patients after 24, 31, and 26 days, seem to be especially susceptible to cardiac toxicity, the
Page 2: Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP T... · ment occurred in all patients after 24, 31, and 26 days, seem to be especially susceptible to cardiac toxicity, the
Page 3: Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP T... · ment occurred in all patients after 24, 31, and 26 days, seem to be especially susceptible to cardiac toxicity, the
Page 4: Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP T... · ment occurred in all patients after 24, 31, and 26 days, seem to be especially susceptible to cardiac toxicity, the
Page 5: Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP T... · ment occurred in all patients after 24, 31, and 26 days, seem to be especially susceptible to cardiac toxicity, the
Page 6: Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP T... · ment occurred in all patients after 24, 31, and 26 days, seem to be especially susceptible to cardiac toxicity, the

Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP I... · SUt,MARY OF PROTOCOL AND STUDY PROCEDURES B. c. Inves t i ga tor Dr. J. P. Coulaud ... Median Range Weight (kg) Mean

Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP I... · SUt,MARY OF PROTOCOL AND STUDY PROCEDURES B. c. Inves t i ga tor Dr. J. P. Coulaud ... Median Range Weight (kg) Mean

Documents
2. SYNOPSIS - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP L... · 2. SYNOPSIS Name of Sponsor/Company: UCB Pharma SA Belgium Individual Study Table Referring to Module

2. SYNOPSIS - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP L... · 2. SYNOPSIS Name of Sponsor/Company: UCB Pharma SA Belgium Individual Study Table Referring to Module

Documents
COMPARISON OF RESISTANT, TOLERANT, AND SUSCEPTIBLE …

COMPARISON OF RESISTANT, TOLERANT, AND SUSCEPTIBLE …

Documents
Trial DXV037 - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP I... · Trial No.: DXV03î13 December 1995 S1 of6 SYNOPSIS In the present trial iodixanol (Vlsnequeo) was investigated

Trial DXV037 - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP I... · Trial No.: DXV03î13 December 1995 S1 of6 SYNOPSIS In the present trial iodixanol (Vlsnequeo) was investigated

Documents
Ii - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP F/Foscarnet... · The safety and efficacy of foseamet for prevention of cytomegalovirus (CMV) infection was ... We report

Ii - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP F/Foscarnet... · The safety and efficacy of foseamet for prevention of cytomegalovirus (CMV) infection was ... We report

Documents
STUDY DRUG - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP T...Thus, the girls' peak response of luteinizing hormone (LH) to a standard gonadotropin-releasing hormone (GnRH)

STUDY DRUG - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP T...Thus, the girls' peak response of luteinizing hormone (LH) to a standard gonadotropin-releasing hormone (GnRH)

Documents
JLtn ..I.. JUllUU ~,-,0THERAPY· - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP P/Proxymetacaine... · ..I.. JUllUU 'fALS OF ... h'lr Variant of Guillain-Barr4 Syndrom'l

JLtn ..I.. JUllUU ~,-,0THERAPY· - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP P/Proxymetacaine... · ..I.. JUllUU 'fALS OF ... h'lr Variant of Guillain-Barr4 Syndrom'l

Documents
Projet susceptible d’augmenter les - AGRCQ

Projet susceptible d’augmenter les - AGRCQ

Documents
Final Report 27.10 - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP H/human normal... · Panartentis nodosa and Panartentis nodosa afier resection of 213 of stomach, cataract

Final Report 27.10 - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP H/human normal... · Panartentis nodosa and Panartentis nodosa afier resection of 213 of stomach, cataract

Documents
Paroxetine 29060 - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP P/Paroxetine/Paroxetine-29060-329...Paroxetine 29060 A Multi-center, Double-blind, Placebo Controlled Study

Paroxetine 29060 - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP P/Paroxetine/Paroxetine-29060-329...Paroxetine 29060 A Multi-center, Double-blind, Placebo Controlled Study

Documents
coffiL - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP I... · 2014. 6. 11. · coffiL Reference 8 APPROYED Nycomed lnc. Research and Development '\ilayne, Pennsylvania

coffiL - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP I... · 2014. 6. 11. · coffiL Reference 8 APPROYED Nycomed lnc. Research and Development '\ilayne, Pennsylvania

Documents
18986389.pdf - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP T/treosulfan... · tember 2007 in two Centres (Oncoematologia Pediatrica, Pavia and Centro Trapianti Midollo

18986389.pdf - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP T/treosulfan... · tember 2007 in two Centres (Oncoematologia Pediatrica, Pavia and Centro Trapianti Midollo

Documents
Strattera Summary 8160 - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP A/Atomoxetine... · aged 6 through 16 years who met the Diagnostic and Statistical Manual of Mental

Strattera Summary 8160 - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP A/Atomoxetine... · aged 6 through 16 years who met the Diagnostic and Statistical Manual of Mental

Documents
DF73D061 - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP M/Mesna... · 2014. 6. 11. · Title: DF73D061 Author: LOGVINOFF-POIDATZ M.M. Subject: 4549 Keywords: Part : 0,Pages

DF73D061 - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP M/Mesna... · 2014. 6. 11. · Title: DF73D061 Author: LOGVINOFF-POIDATZ M.M. Subject: 4549 Keywords: Part : 0,Pages

Documents
Penicillin-Susceptible, Oxidase-Negative, Nonhemolytic ...downloads.hindawi.com/journals/criid/2017/2578082.pdf · Penicillin-Susceptible, Oxidase-Negative, Nonhemolytic, Nonmotile

Penicillin-Susceptible, Oxidase-Negative, Nonhemolytic ...downloads.hindawi.com/journals/criid/2017/2578082.pdf · Penicillin-Susceptible, Oxidase-Negative, Nonhemolytic, Nonmotile

Documents
Global Antimicrobial Resistance Surveillance System (GLASS) · Klebsiella spp. Susceptible Enterobacter spp. Susceptible Pseudomonas aeruginosa Susceptible Acinetobacter spp. Susceptible

Global Antimicrobial Resistance Surveillance System (GLASS) · Klebsiella spp. Susceptible Enterobacter spp. Susceptible Pseudomonas aeruginosa Susceptible Acinetobacter spp. Susceptible

Documents
susceptible wheat seedlings response to Puccinia

susceptible wheat seedlings response to Puccinia

Documents
SCREENING OF MALIGNANT HYPERTHERMIA SUSCEPTIBLE - … · screening of malignant hyperthermia susceptible families by creatine phosphokinase measurement and other clinical investigations

SCREENING OF MALIGNANT HYPERTHERMIA SUSCEPTIBLE - … · screening of malignant hyperthermia susceptible families by creatine phosphokinase measurement and other clinical investigations

Documents
Progression of phosphine resistance in susceptible

Progression of phosphine resistance in susceptible

Documents
ete - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP F/Framycetin/Cl… · 438 BULL,"'l'IN 1)1'5 ~OCIi7rE:S D'OPHT.~I.MOLOGrE confirma la resistance de ces germes a In p!upart

ete - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP F/Framycetin/Cl… · 438 BULL,"'l'IN 1)1'5 ~OCIi7rE:S D'OPHT.~I.MOLOGrE confirma la resistance de ces germes a In p!upart

Documents
III - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP F...IV weekly for 3-4 weeks and then 400-800mg qds PO for 3 months) in conjunction with IVIG (weekly till D+35 and then

III - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP F...IV weekly for 3-4 weeks and then 400-800mg qds PO for 3 months) in conjunction with IVIG (weekly till D+35 and then

Documents
N CONFIDEilTIAL - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP I... · The quality of overall diagnostic inforsration in the iodixa¡rol27O mg Vnrl group was classified

N CONFIDEilTIAL - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP I... · The quality of overall diagnostic inforsration in the iodixa¡rol27O mg Vnrl group was classified

Documents
How Susceptible Are You?

How Susceptible Are You?

Documents
Perturbative solution to susceptible-infected-susceptible epidemics

Perturbative solution to susceptible-infected-susceptible epidemics

Documents
Qualities of Person susceptible to persuaders

Qualities of Person susceptible to persuaders

Documents
PM Health Effects: Susceptible Populations

PM Health Effects: Susceptible Populations

Documents
Cefazolin inoculum effect and methicillin-susceptible

Cefazolin inoculum effect and methicillin-susceptible

Documents
Manual for Zonation on Areas Susceptible

Manual for Zonation on Areas Susceptible

Documents
Treatment of neonatal conjunctivitis.pdf - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP C... · Treatment of Neonatal Conjunctivitis ... Us and no , ig"a 01 dacryocystitis,

Treatment of neonatal conjunctivitis.pdf - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP C... · Treatment of Neonatal Conjunctivitis ... Us and no , ig"a 01 dacryocystitis,

Documents
Confident i a1 - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP T...4 Confident i a1 SUMMARY Studv Title and Investiqators A Mu1 ticentre Study of D-Trp'-LHRH Mi crospheres

Confident i a1 - Europaart45-paediatric-studies-docs.ema.europa.eu/GROUP T...4 Confident i a1 SUMMARY Studv Title and Investiqators A Mu1 ticentre Study of D-Trp'-LHRH Mi crospheres

Documents